<SEC-DOCUMENT>0001171843-25-004265.txt : 20250702
<SEC-HEADER>0001171843-25-004265.hdr.sgml : 20250702
<ACCEPTANCE-DATETIME>20250702060025
ACCESSION NUMBER:		0001171843-25-004265
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20250701
FILED AS OF DATE:		20250702
DATE AS OF CHANGE:		20250702

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evaxion A/S
		CENTRAL INDEX KEY:			0001828253
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			G7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39950
		FILM NUMBER:		251098255

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		DR NEERGAARDS VEJ 5F
		CITY:			HOERSHOLM
		PROVINCE COUNTRY:   	G7
		BUSINESS PHONE:		4552656554

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		DR NEERGAARDS VEJ 5F
		CITY:			HOERSHOLM
		PROVINCE COUNTRY:   	G7

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Evaxion Biotech A/S
		DATE OF NAME CHANGE:	20201014
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_070125.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html><head><title></title></head><body style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><div align="center"><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;">&#160;</div></div><p style="font-size: 14pt;" align="center"><strong>UNITED STATES</strong><br /><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington, D.C. 20549</strong></p><p style="font-size: 14pt; text-transform: uppercase;" align="center"><strong>Form 6-K</strong></p><p style="text-align: center;"><strong></strong></p><p style="text-align: center;"><strong>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="text-align: center;"><strong></strong><strong>For the month of July 2025</strong></p><p style="text-align: center;">Commission File Number: <strong>001-39950</strong></p><p style="text-align: center;"><font><font style="font-size: 12pt;"><strong>Evaxion A/S</strong></font></font><br />(Exact Name of Registrant as Specified in Its Charter)</p><p style="text-align: center;"><strong>Dr. Neergaards Vej 5f<br />DK-2970&#160;Hoersholm<br />Denmark</strong><br />(Address of principal executive office)</p></div><p>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</p><p style="text-align: center;">Form 20-F [&#160;X ] &#160;&#160;&#160;&#160;&#160;Form 40-F [&#160;&#160; ]</p><p><!--<p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <u>&#160;</u></p><p><strong>Note:&#160;</strong>Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.</p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <u>&#160;</u></p><p><strong>Note:&#160;</strong>Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.&#160;</p>--></p><hr style="break-after: page;" noshade="noshade" /><p style="text-align: center;"><strong>INCORPORATION BY REFERENCE</strong></p><p>This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S's (the "Company") registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</p><p><font><p><strong>Executive Management Changes</strong></p><p>In a Press Release dated July 1, 2025, Evaxion A/S (the &#8220;Company&#8221;), announced certain executive management changes.</p><p>The Company announced that Christian Kanstrup has resigned as the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;).&#160;</p><p>Dr. Birgitte R&#248;n&#248;, Evaxion&#8217;s Chief Scientific Officer, has been appointed interim CEO. Dr. R&#248;n&#248; has been with the Company since 2018 and brings deep scientific and strategic expertise to the role.</p><p>The Company also announced that Mr. Thomas F. Schmidt has been appointed Chief Financial Officer (&#8221;CFO&#8221;). He joined Evaxion in November 2024 as interim CFO and brings strong financial acumen and capital markets experience.</p><p>Furnished as Exhibit 99.1 to this Report on Form&#160;6-K&#160;is the Company&#8217;s Press Release dated July 1, 2025, related to the change in the Company&#8217;s Executive Management.</p><p><strong>Exhibits</strong></p><table style="font-size: 10pt;" border="0" cellspacing="0" cellpadding="0"><tr><td style="text-decoration: underline;" valign="bottom"><font style="font-size: 10pt;">Exhibit No.</font></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td style="text-decoration: underline;" valign="bottom"><font style="font-size: 10pt;">Description</font></td></tr><tr><td>&#160;</td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td><font style="font-size: 10pt;">&#160;</font></td></tr><tr><td><font style="font-size: 10pt;"><a href="exh_991.htm">99.1</a></font></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td><font style="font-size: 10pt;"><a href="exh_991.htm">Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology&#8482; platform and portfolio</a> </font></td></tr></table></font></p><hr style="page-break-after: always;" noshade="noshade" /><p style="text-align: center;"><strong>SIGNATURES</strong></p><p>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="font-family: Times New Roman; font-size: 10pt;" border="0" width="100%" cellspacing="0" cellpadding="0"><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td style="text-decoration: underline; text-align: left;" align="center" width="47%"><strong>Evaxion A/S</strong></td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%">(Registrant)</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%"></td></tr><tr valign="top"><td width="47%">Date: July 1, 2025</td><td width="6%">&#160;</td><td width="6%">By:</td><td style="text-decoration: underline; text-align: left;" align="center" width="47%">/s/ Birgitte R&#248;n&#248;&#160;&#160;&#160;&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%">Birgitte R&#248;n&#248;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%">Interim Chief Executive Officer</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%"></td></tr></table></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252" ><meta name="GENERATOR" content="MSHTML 8.00.7601.18094" ></head><body bgcolor="#ffffff"><p style="text-align: right;"><font style="font-size: 10pt"><b>EXHIBIT
                                            99.1</b></font></p><p style="text-align: center;"><font style="font-size: 10pt"><b>Evaxion
                                            announces changes to Executive Management to optimize the value of proprietary AI-Immunology&#153;
                                            platform and portfolio</b></font></p><p style="text-align: center;" ></p><p><font style="font-size: 10pt"><ul></font><li><font style="font-size: 10pt"><b>Chief Executive Officer (CEO) Christian Kanstrup steps down&#160;</b></font></li><li style="text-align:justify;"><font style="font-size: 10pt"><b>Chief
                                            Scientific Officer Birgitte R&#248;n&#248; appointed interim CEO and search for new CEO has
                                            commenced</b></font></li><li style="text-align:justify;"><font style="font-size: 10pt"><b>Thomas
                                            Schmidt appointed permanent Chief Financial Officer</b><br></font></li></ul>  <p align="justify"><font style="font-size: 10pt">COPENHAGEN,
                                            Denmark, July 1, 2025 - Evaxion A/S (NASDAQ: EVAX) (&#8220;Evaxion&#8221;), a clinical-stage
                                            TechBio company specializing in developing AI-Immunology&#153; powered vaccines, announces
                                            several key executive management changes to optimize value from its proprietary AI-Immunology&#153;
                                            platform and pipeline.</font></p>  <p align="justify"><font style="font-size: 10pt">Christian
                                            Kanstrup has stepped down as Chief Executive Officer (CEO) and Evaxion has initiated the
                                            search for a new permanent CEO to lead its next phase of growth and to accelerate value creation
                                            from its AI-based technologies and assets developed over the past 17 years.</font></p>  <p align="justify"><font style="font-size: 10pt">Dr.
                                            Birgitte R&#248;n&#248;, Evaxion&#8217;s Chief Scientific Officer, has been appointed interim
                                            CEO. Dr. R&#248;n&#248; has been with Evaxion since 2017 and joined its Executive Management
                                            in 2021. She brings deep scientific and strategic expertise to the role.</font></p>  <p align="justify"><font style="font-size: 10pt">Thomas
                                            Schmidt has been appointed permanent Chief Financial Officer (CFO). He joined Evaxion in
                                            November 2024 as interim CFO and brings strong financial acumen and capital markets experience.</font></p>  <p align="justify"><font style="font-size: 10pt">&#8220;Evaxion
                                            is in a strong position as we continue our focus to unlock the full business potential of
                                            our AI-Immunology&#153; platform. I would like to thank Christian for his valuable contributions
                                            during a pivotal phase in Evaxion&#8217;s ongoing transformation.</font></p>  <p align="justify"><font style="font-size: 10pt">I
                                            also thank Birgitte for accepting her appointment to interim CEO, ensuring leadership continuity
                                            based on her four years as a member of Executive Management and a key contributor to our
                                            corporate strategy. Birgitte will be supported in daily management by Thomas Schmidt with
                                            his financial expertise and a solid understanding of our operations and leadership capabilities.</font></p>  <p align="justify"><font style="font-size: 10pt">The
                                            Board of Directors will carry through a diligent search for a new CEO with a strong business
                                            development focus, proven transformational leadership, and the executional capabilities required
                                            to drive strategic partnerships,&#8221; says Marianne S&#248;gaard, Chairman of the Board
                                            at Evaxion.</font></p>  <p align="justify"><font style="font-size: 10pt">&#8220;It
                                            has been a pleasure to serve as CEO of Evaxion and working with the tremendous team of employees
                                            to ensure progress in numerous areas during my time here. I hope the progress will continue
                                            and look forward to following Evaxion from the outside&#8221;, says Christian Kanstrup.</font></p>  <p align="justify"><font style="font-size: 10pt"><b>Contact
                                            information</b>&#160;<br>Evaxion A/S<br>Mads Kronborg<br>Vice President, Investor Relations
                                            &amp; Communication<br>+45 53 54 82 96 <br>mak@evaxion.ai</font></p>  <p align="justify"><font style="font-size: 10pt"><b>About
                                            Evaxion</b> <br>Evaxion is a pioneering TechBio company based upon its AI platform, AI-Immunology&#153;.
                                            Evaxion&#8217;s proprietary and scalable AI prediction models harness the power of artificial
                                            intelligence to decode the human immune system and develop novel immunotherapies for cancer,
                                            bacterial diseases, and viral infections. Based upon AI-Immunology&#153;, Evaxion has developed
                                            a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious
                                            disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is
                                            committed to transforming patients&#8217; lives by providing innovative and targeted treatment
                                            options. For more information about Evaxion and its groundbreaking AI-Immunology&#153; platform
                                            and vaccine pipeline, please visit our website.</font></p>  <p align="justify"><font style="font-size: 10pt"><b>Forward-looking
                                            statement</b>&#160;<br>This&#160;announcement contains forward-looking statements&#160;within
                                            the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of
                                            the Securities Exchange Act of 1934, as amended.&#160;The words&#160;&#8220;target,&#8221;
                                            &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;hope,&#8221; &#8220;aim,&#8221; &#8220;intend,&#8221;
                                            &#8220;may,&#8221; &#8220;might,&#8221; &#8220;anticipate,&#8221; &#8220;contemplate,&#8221;
                                            &#8220;continue,&#8221; &#8220;estimate,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221;
                                            &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;can have,&#8221;
                                            &#8220;likely,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; and
                                            other words and terms of similar meaning&#160;identify forward-looking statements.&#160;Actual
                                            results may differ materially from those indicated by such forward-looking statements as
                                            a result of various factors, including, but not limited to, risks related to: our financial
                                            condition and need for additional capital; our development work; cost and success of our
                                            product development activities and preclinical and clinical trials; commercializing any approved
                                            pharmaceutical product developed using our AI platform technology, including the rate and
                                            degree of market acceptance of our product candidates; our dependence on third parties including
                                            for conduct of clinical testing and product manufacture; our inability to enter into partnerships;
                                            government regulation; protection of our intellectual property rights; employee matters and
                                            managing growth; our ADSs and ordinary shares,&#160;the impact of international economic,
                                            political, legal, compliance, social and business factors, including inflation, and the effects
                                            on our&#160;business from other significant geopolitical and macro-economic events;&#160;and
                                            other uncertainties affecting our business operations and financial condition.&#160;For a
                                            further discussion of these risks, please refer to the risk factors included in our most
                                            recent Annual Report on Form 20-F&#160;and other filings&#160;with the US Securities and
                                            Exchange Commission (SEC), which are available at&#160;<b>www.sec.gov</b>.&#160;We do not
                                            assume any obligation to update any forward-looking statements except as required by law.&#160;</font></p> </p><p ></p></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
